CAMPBELL, CA–(Marketwired – Apr 14, 2016) – Friendable, Inc. (OTC PINK: FDBL), a mobile application developer, is pleased to announce that its submission of a major app update for Friendable iOS/iPhone users has been approved and is now available in the Apple iTunes App Store. These major app updates completed in the iOS version of the Friendable app were designed to spur new user downloads and registrations.
Among the upgrades included are the following features:
Users can now sign in and connect using Facebook, the world’s largest social network.
A new proprietary location database connected to Google Places.
An all-new registration and onboarding process, making the signup process faster and simpler.
Event selectors are now icon based, adding ease and charm to each action.
Updated User Interface (UI) to the all-important member profile screens.
“Our entire team is in agreement, these updates significantly improve the user experience for iOS users making the Friendable app even friendlier,” said Robert Rositano, Jr., CEO, Friendable, Inc. “The updated integration with Facebook is a big deal for us, among various other advancements and by using a trusted verification platform like Facebook to incent users to login using this method, is just one more feature that will improve the user experience. We expect these changes to significantly increase new user signups and provide the foundation to boost revenue opportunities as we continue our focus on overall user population and growth.”
About Friendable: Friendable Inc. is a mobile application developer whose Friendable app makes it simple and easy for users to make connections and meet new friends using shared interests and location. These interactions allow Friendable to generate ad revenue by providing advertisers such as restaurants, bars and events with the opportunity to reach potential customers when it matters most: which is when Friendable users are nearby and searching for something to do.
Cautionary Language Concerning Forward-Looking Statements This press release contains forward-looking statements. The words or phrases “would be,” “will allow,” “intends to,” “will likely result,” “are expected to,” “will continue,” “is anticipated,” “estimate,” “project,” or similar expressions are intended to identify “forward-looking statements.” Actual results could differ materially from those projected by Friendable, Inc. The iTunes rankings should not be construed as an indication in any way whatsoever of the future value of the Friendable’s common stock or its present or future financial condition. The public filings of Friendable, Inc. made with the Securities and Exchange Commission may be accessed at the SEC’s Edgar system atwww.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Friendable, Inc. cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, Friendable, Inc. does not undertake, and Friendable, Inc. specifically disclaims any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
All information contained herein as well as on the EmergingGrowth.com website is obtained from sources believed to be reliable but not guaranteed to be accurate or all-inclusive. All material is for informational purposes only, is only the opinion of EmergingGrowth.com and should not be construed as an offer or solicitation to buy or sell securities. EmergingGrowth.com may either hold a stock position in or have been compensated by or for a company or companies discussed in this article. EmergingGrowth.com does not have a stock position in any securities discussed in this article. Please view our full disclosure which can be found here,https://www.emerginggrowth.com/disclosure-3325/. Please consult an investment professional before investing in anything viewed within. When EmergingGrowth.com is long shares it will sell those shares. In addition, please make sure you read and understand the Terms of Use, Privacy Policy and the Disclosure posted on the EmergingGrowth.com website.
In 2016, Moderna received $8 million with the potential for up to $125 million from the Biomedical Advanced Research and Development Authority, a component of the U.S. Department of Health and Human Services, to accelerate development of an mRNA vaccine for Zika. (The company is still working on that project.)What makes the bankrolling of Moderna’s Covid-19 vaccine so extraordinary, Foroohar said, was the scale, which “reflects how unusual the pandemic is and the fact that this is very literally a once-in-a-lifetime event.”
The following year, it was bought by Gilead NASDAQ: GILD and its immunotherapy subsidiary, Kite, for $567 million. Since then, Kite has begun recruiting for a clinical trial of its solid tumor CAR-T candidate, but it has not yet moved past Phase 1.
The three-year collaboration, announced Wednesday, has initial funding of $7.28 million.Current gene therapy approaches being developed for sickle cell disease are complex, enormously expensive, and bespoke, crafting treatments for individual patients one at a time. The collaboration aims to instead create an off-the-shelf treatment that bypasses many of the steps of current approaches, in which cells are removed and processed outside the body before being returned to patients.
A Virtual Care Platform Covering Diagnosis to Treatment without leaving your Home
The camera on your phone is more powerful than you know. The infrared aspect...
Efficacy rates for China’s Covid vaccines have been found to be lower than those developed by Pfizer-BioNTech (NYSE PFE) (NASDAQ:BNTX) and Moderna. (NASDAQ MRNA) Earlier this month, the director of the Chinese Center for Disease Control publicly acknowledged that Chinese vaccines “don’t have very high protection rates” and that they were considering giving people different Covid shots to boost vaccine efficacy.
The chief medical officer of BioNTech (NASDAQ BNTX) told CNBC on Wednesday that people will likely need a third shot of its two-dose Covid-19 vaccine as immunity against the virus wanes, agreeing with previous comments made by Pfizer CEO Albert Bourla. Dr. Ozlem Tureci, co-founder and CMO of BioNTech, which developed a Covid vaccine with Pfizer (NYSE: PFE), said she also expects people will need to get vaccinated against the coronavirus annually, like for the seasonal flu.
From January 2020 through January of this year, Moderna stock has dropped significantly three times. And each time, it recovered and climbed above its previous record high. It looks like that now may be happening for the fourth time. This may be a pattern of investors locking in profits, then repurchasing shares at a lower price -- and newcomers jumping aboard too.
Avalon GloboCare Corp. (NASDAQ: AVCO) is a clinical-stage, vertically integrated, leading CellTech bio-developer with potential blockbuster prospects in immune effector cell therapy, exosome technology, as well as COVID-19 related diagnostics and therapeutics. Avalon also provides strategic advisory and outsourcing services to facilitate and enhance its clients' growth and development, as well as competitiveness in healthcare and CellTech industry markets.
As big pharma races to save millions of lives there is a smaller less known “sleeping giant” in the CAR-T space developing advanced S-layer technology with limitless applications in the key development of an intranasal vaccine.
Now, due to “regulatory uncertainties” and the time and resources needed to provide the additional data, Merck said it decided to discontinue the development of the drug and instead focus its efforts on advancing its other Covid-19 drug as well as accelerating production of the Johnson & Johnson vaccine.